Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Green tea shows promise in preventing diabetes in obese kids

NCT ID NCT06229795

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding green tea extract to standard metformin treatment can improve insulin resistance in obese children aged 10-18 with prediabetes. 90 participants were split into two groups: one received metformin alone, the other added green tea extract three times daily for 4 months. Researchers measured blood sugar, insulin resistance, and other health markers to see if green tea helps prevent progression to type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Green tea leaf extract (decaffeinated) and metformin
What this could lead to
If it works, this could point toward a simple, natural supplement to help prevent type 2 diabetes in obese children with prediabetes.
What could go wrong
This is a small, early-phase trial with only 90 participants, so results may not apply to everyone. Green tea can cause liver problems or stomach pain in some people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

90 people

The number who actually took part.

Started

Nov 2023

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Homeostatic Model Assessment for Insulin Resistance (HOMA IR) \>2.5 2. BMI \>= 95th percentile according to CDC percentile charts 3. Age from 10 to 18 years. 4. Willing to sign a written informed consent through their caregivers. 5. Absence of sensitivity and/or known allergies for green tea. Exclusion Criteria: 1. Homeostatic Model Assessment for Insulin Resistance (HOMA IR) \<2.5 2. Endogenous obesity eg; thyroid dysfunction and adrenal glands dysfunction. 3. Presence of any other comorbidities as: cardiovascular, renal, liver etc…

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance obesity disorder prediabetes syndrome type 2 diabetes mellitus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prediabetes

Contacts and locations

Locations

  • El-Demerdash hospital

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.